Latest Conference Articles

Lungcast hits the road, as the director of pulmonary and critical care medicine at University of Vermont joins to discuss ATS 2023 headlines and the Airways Clinical Research Network.

At ATS 2023, Dr. Galiatsatos illuminates what makes lung cancer screening different and how the screening approach is changing.

In an interview at ATS 2023, Dr. Rutland stresses the importance of studying the immune system's response to various diseases, emphasizing the potential impact of pipeline molecules.

A post hoc analysis shows benralizumab was even more efficacious in patients with concomitant nasal polyps at both 6 and 12 months.

Dr. Panagis Galiatsatos explains the new lung cancer screening aims to address the disparities of disease onset and progression across different racial populations.

Though still not in abundance on the market, ICS/LAMA/LABA triple-therapy single inhaler treatment options are becoming more valued for COPD exacerbation and comorbid disease risk.

An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

Unlike other screenings, lung cancer screening is new and patients need to know what happens next, according to Dr. Panagis Galiatsatos.

Promising results from the ATS Conference suggest that AD109, an oral treatment for obstructive sleep apnea, demonstrated significant reduction of AHI and potential mitigation of daytime fatigue.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

There is no additional risk of developing new cancers for patients treated with IBD medications.

AD109 shows the potential to address an unmet need in obstructive sleep apnea treatment.

RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

In this interview, Friedman described his conference presentation on treating atopic dermatitis through telemedicine to address the disparities in care that are visible around the world.

Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.

There was a reduction in medical costs that offset the increased pharmacy costs in the patients who were treated with rifaximin.

In 2022, dupilumab became the first treatment approved by the US Food and Drug Administration for the treatment of patients with EoE.

In the induction trial, guselkumab resulted in a higher rate of clinical remission, as well as symptomatic remission, clinical response, endoscopic improvement, and histo-endoscopic mucosal improvement at week 12.

Guselkumab induction treatment resulted in significantly greater proportions of patients achieving symptomatic remission, clinical response, endoscopy improvement, and histo-endoscopic mucosal improvement at week 12 and symptomatic remission at week 4 compared to placebo.

The lowest screening completion rate was in the colonoscopy invitation group at 14.5% and the patients offered a choice were more likely to complete screening of any kind, compared to either group of patients offered only 1 screening modality.

There was a significant reduction in severity score for diarrhea, constipation, abdominal pain, epigastric pain, bloating, vomiting, and acid reflux in participants who reported digestive problem improvements followed by SIM01 treatment.

RBX2660 was originally approved by the FDA in 2022 and came to market in January 2023.

Recent studies have indicated that using adenoma per colonoscopy as a metric could help better forecast the risk of colon cancer.